Title:
Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Title:
Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Title:
A randomized multicenter Phase II trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF in patients with Triple Negative Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Title:
A Retrospective Chart Review to Evaluate the Clinical Outcomes of Breast Cancer Patients Treated with Xeloda and Radiation Therapy on the T0-0401 Clinical Trial at Texas Oncology - Sammons Cancer Center View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
A Retrospective Chart Review to Evaluate the Clinical Outcomes of Breast Cancer Patients Treated with Xeloda and Radiation Therapy on the T0-0401 Clinical Trial at Texas Oncology - Sammons Cancer Center View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Title:
A Retrospective Chart Review to Evaluate the Clinical Outcomes of Breast Cancer Patients Treated with Xeloda and Radiation Therapy on the T0-0401 Clinical Trial at Texas Oncology - Sammons Cancer Center View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Title:
A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Title:
A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Title:
Treatment Plan to Provide Alpelisib for an Individual Adult Patient (QK) with Locally Advanced or Metastatic Cancer Resistant or Refractory to Available Treatment Options View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
Treatment Plan to Provide Alpelisib for an Individual Adult Patient (QK) with Locally Advanced or Metastatic Cancer Resistant or Refractory to Available Treatment Options View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Title:
Treatment Plan to Provide Alpelisib for an Individual Adult Patient (QK) with Locally Advanced or Metastatic Cancer Resistant or Refractory to Available Treatment Options View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Title:
Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View
Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View
Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: III
Title:
Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View
Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)
Indication:
Breast Cancer
Location:
Texas Oncology-Sherman
Phase: III
Title:
Ph1b Abemaciclib + SOC in mBC View
Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b Abemaciclib + SOC in mBC View
Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b Abemaciclib + SOC in mBC View
Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: III
Title:
Sacituzumab Govitecan(SASSY) vs PC mTNBC View
Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
Sacituzumab Govitecan(SASSY) vs PC mTNBC View
Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
Sacituzumab Govitecan(SASSY) vs PC mTNBC View
Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
Sacituzumab Govitecan(SASSY) vs PC mTNBC View
Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Sacituzumab Govitecan(SASSY) vs PC mTNBC View
Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Sacituzumab Govitecan(SASSY) vs PC mTNBC View
Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Sacituzumab Govitecan(SASSY) vs PC mTNBC View
Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Phase: III
Title:
Sacituzumab Govitecan(SASSY) vs PC mTNBC View
Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: III
Title:
PHIII AuxLymphDisect VS AuxRad Node+Brst View
Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
PHIII AuxLymphDisect VS AuxRad Node+Brst View
Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: III
Title:
PHIII AuxLymphDisect VS AuxRad Node+Brst View
Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)
Indication:
Breast Cancer
Location:
Texas Oncology-Sherman
Phase: III
Title:
Ph1 SGN-LIV1A Metastatic BC View
Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 SGN-LIV1A Metastatic BC View
Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 SGN-LIV1A Metastatic BC View
Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View
Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Mesquite
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Title:
Cape/tras +/- ONT-380 HER2+ mBC View
Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Phase: II
Title:
Cape/tras +/- ONT-380 HER2+ mBC View
Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: II
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Destiny1:Ph2 DS-8201a HER2+ unresect/mBC View
Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Destiny1:Ph2 DS-8201a HER2+ unresect/mBC View
Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: II
Title:
Destiny1:Ph2 DS-8201a HER2+ unresect/mBC View
Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: II
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Mesquite
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: III
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Sherman
Phase: III
Title:
Ph 1b2 LIV1A+Pembro 1L mTNBC View
Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
Ph 1b2 LIV1A+Pembro 1L mTNBC View
Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I/II
Title:
Ph 1b2 LIV1A+Pembro 1L mTNBC View
Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo View
Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I/II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: II